Skip to main content
Erschienen in: BMC Pregnancy and Childbirth 1/2021

Open Access 01.12.2021 | Correction

Correction to: Maternal HBsAg carriers and pregnancy outcomes: a retrospective cohort analysis of 85,190 pregnancies

verfasst von: Yulong Zhang, Jiacheng Chen, Tingting Liao, Siwen Chen, Jianying Yan, Xiaoqian Lin

Erschienen in: BMC Pregnancy and Childbirth | Ausgabe 1/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
Yulong Zhang and Jiacheng Chen contributed equally to this work.
The original article can be found online at https://​doi.​org/​10.​1186/​s12884-020-03257-4.
Correction to: BMC Pregnancy Childbirth 20, 724 (2020)
https://doi.org/10.1186/s12884-020-03257-4
Following publication of the original article [1], the authors reported an error in Tables 1, 2 and 3 headers. The correct tables are given below.
Table 1
Baseline characteristics of the included patientsa
 
HBV-positive
(n = 9699)
HBV-negative
(n = 73,076)
P value
OR
Maternal age (yrs, mean ± SD)
30.33 ± 4.50
30.28 ± 4.45
P = 0.30
 
Gestational age (weeks, mean ± SD)
38.18 ± 2.96
38.17 ± 3.51
P = 0.76
 
Gravidity
 1
3323 (34.26%)
28,076 (38.42%)
P < 0.001
0.84 (0.80,0.87)
  > 1
6376 (65.74%)
45,000 (61.58%)
P < 0.001
1.20 (1.15,1.25)
Parity
 1
82 (0.85%)
760 (1.04%)
P = 0.07
0.81 (0.65,1.02)
  > 1
9617 (99.15%)
72,316 (98.96%)
P = 0.07
1.23 (0.98,1.55)
Mode of delivery
 Instrumental vaginal
1903 (19.62%)
14,009 (19.17%)
P = 0.29
1.03 (0.98,1.09)
 Cesarean section
3380 (34.85%)
24,729 (33.84%)
P = 0.05
1.05 (1.00,1.09)
 Vaginal delivery
4373 (45.09%)
33,907 (46.40%)
P = 0.01
0.95 (0.91,0.99)
 Regional analgesia
43 (0.44%)
431 (0.59%)
P = 0.07
0.75 (0.55,1.03)
Birth weight(g)
  < 3000
2855 (29.44%)
20,571 (28.15%)
P = 0.008
1.06 (1.02,1.122)
 3000–3499
4026 (41.51%)
30,721 (42.04%)
P = 0.32
0.98 (0.94,1.02)
 3500–3999
2231 (23.00%)
17,085 (23.38%)
P = 0.41
0.98 (0.93,1.03)
  ≥ 4000
388 (6.05%)
2718 (6.43%)
P = 0.17
1.08 (0.97,1.20)
Table 2
The association between HBV positive pregnancies and outcomes
 
HBV-positive
(n = 9699)
HBV-negative
(n = 73,076)
P value
OR
Gestational hypertension
157 (1.62%)
1421 (1.94%)
P = 0.028
0.83 (0.70,0.98)
Preeclampsia
139 (1.43%)
1302 (1.78%)
P = 0.014
0.80 (0.67,0.96)
HELLP syndrome
5 (0.05%)
48 (0.07%)
P = 0.605
0.78 (0.31,1.97)
PPROM
2577 (26.57%)
20,776 (28.43%)
P < 0.001
0.91 (0.87,0.96)
Postpartum hemorrhage
218 (2.25%)
1424 (1.95%)
P = 0.047
1.16 (1.00,1.34)
GDM
1663 (17.15%)
11,982 (16.40%)
P = 0.062
1.06 (1.00,1.12)
ICP
149 (1.54%)
334 (0.46%)
P = 0.001
3.40 (2.80,4.13)
placental abruption
140 (1.44%)
905 (1.24%)
P = 0.089
1.17 (0.98,1.40)
Premature birth
1158 (11.94%)
8424 (11.53%)
P = 0.234
1.04 (0.97,1.11)
Small for gestational age
392 (0.22%)
3165 (0.19%)
P = 0.192
0.93 (0.84,1.04)
Table 3
Gestational complications in Vaginal delivery
 
HBV-positive
(n = 6447)
HBV-negative
(n = 49,206)
P
OR
Gestational hypertension
88 (1.30%)
804 (1.41%)
P = 0.106
0.83 (0.67, 1.04)
Preeclampsia
49 (0.76%)
479 (0.97%)
P = 0.096
0.78 (0.58,1.05)
HELLP syndrome
1 (0.02%)
6 (0.01%)
P = 0.851
1.27 (0.15,10.57)
PPROM
2018 (31.30%)
16,808 (34.16%)
P < 0.001
0.88 (0.83,0.93)
Postpartum hemorrhage
178 (2.76%)
1151 (2.34%)
P = 0.037
1.19 (1.01,1.39)
GDM
1079 (16.74%)
7811 (15.87%)
P = 0.076
1.07 (0.99,1.14)
ICP
78 (1.21%)
161 (0.33%)
P < 0.001
3.73 (2.84,4.90)
Placental abruption
101 (1.57%)
537 (1.09%)
P < 0.001
1.44 (1.16,1.79)
Premature birth
669 (10.38%)
4546 (9.24%)
P = 0.003
1.14 (1.04,1.24)
Small for gestational age
265 (4.11%)
1817 (3.69%)
P = 0.096
1.12 (0.98,1.28)
Statement “YLZ and JCC contributed equally to this work.” in the Authors’ contributions section deleted. “Yulong Zhang and Jiacheng Chen contributed equally to this work.” was inserted as article note.
The original article [1] has been updated.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Correction to: Maternal HBsAg carriers and pregnancy outcomes: a retrospective cohort analysis of 85,190 pregnancies
verfasst von
Yulong Zhang
Jiacheng Chen
Tingting Liao
Siwen Chen
Jianying Yan
Xiaoqian Lin
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
BMC Pregnancy and Childbirth / Ausgabe 1/2021
Elektronische ISSN: 1471-2393
DOI
https://doi.org/10.1186/s12884-021-03630-x

Weitere Artikel der Ausgabe 1/2021

BMC Pregnancy and Childbirth 1/2021 Zur Ausgabe

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Neue S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Gestationsdiabetes: In der zweiten Schwangerschaft folgenreicher als in der ersten

13.05.2024 Gestationsdiabetes Nachrichten

Das Risiko, nach einem Gestationsdiabetes einen Typ-2-Diabetes zu entwickeln, hängt nicht nur von der Zahl, sondern auch von der Reihenfolge der betroffenen Schwangerschaften ab.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.